Terms: = Kidney tumors AND SETD2, ENSG00000181555, 29072 AND Prognosis
48 results:
1. A novel immune-related lncRNA signature predicts the prognosis and immune landscape in ccRCC.
Dai L; Pan D; Jin J; Lv W
Aging (Albany NY); 2024 Mar; 16(6):5149-5162. PubMed ID: 38484738
[TBL] [Abstract] [Full Text] [Related]
2. Identification of molecular characteristics of FUT8 and alteration of core fucosylation in kidney renal clear cell cancer.
Xin Z; Wen X; Zhou M; Lin H; Liu J
Aging (Albany NY); 2024 Jan; 16(3):2299-2319. PubMed ID: 38277230
[TBL] [Abstract] [Full Text] [Related]
3. RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
BMC Urol; 2024 Jan; 24(1):8. PubMed ID: 38172737
[TBL] [Abstract] [Full Text] [Related]
4. Knockdown of setd2 promotes erastin-induced ferroptosis in ccRCC.
Xue W; Jian W; Meng Y; Wang T; Cai L; Yu Y; Yu Y; Xia Z; Zhang C
Cell Death Dis; 2023 Aug; 14(8):539. PubMed ID: 37604811
[TBL] [Abstract] [Full Text] [Related]
5. Investigating the Role of
Xu S; Hu X; Chong Y; Zhu G
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569676
[TBL] [Abstract] [Full Text] [Related]
6. A role for setd2 loss in tumorigenesis through DNA methylation dysregulation.
Javaid H; Barberis A; Chervova O; Nassiri I; Voloshin V; Sato Y; Ogawa S; Fairfax B; Buffa F; Humphrey TC
BMC Cancer; 2023 Aug; 23(1):721. PubMed ID: 37528416
[TBL] [Abstract] [Full Text] [Related]
7. Gene mutation profiling and clinical significances in patients with renal cell carcinoma.
Wang Y; He P; Zhou X; Wang C; Fu J; Zhang D; Liao D; Zhou Z; Wu C; Gong W
Clinics (Sao Paulo); 2023; 78():100259. PubMed ID: 37515929
[TBL] [Abstract] [Full Text] [Related]
8. Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma.
Cotta BH; Choueiri TK; Cieslik M; Ghatalia P; Mehra R; Morgan TM; Palapattu GS; Shuch B; Vaishampayan U; Van Allen E; Ari Hakimi A; Salami SS
Eur Urol; 2023 Aug; 84(2):166-175. PubMed ID: 37085424
[TBL] [Abstract] [Full Text] [Related]
9. Exploration of Morphological Features of Clear Cell Renal Cell Carcinoma With
Liu Y; Li Y; Xu H; Zhou L; Yang X; Wang C
Int J Surg Pathol; 2023 Dec; 31(8):1485-1494. PubMed ID: 36911986
[TBL] [Abstract] [Full Text] [Related]
10. Hybrid Metabolic Activity-Related Prognostic Model and Its Effect on Tumor in Renal Cell Carcinoma.
Yu L; Ding L; Wang ZY; Zhao XZ; Wang YH; Liang C; Li J
J Healthc Eng; 2022; 2022():1147545. PubMed ID: 36591111
[TBL] [Abstract] [Full Text] [Related]
11. Identification and experimental validation of a tumor-infiltrating lymphocytes-related long noncoding RNA signature for prognosis of clear cell renal cell carcinoma.
Deng Y; Guo K; Tang Z; Feng Y; Cai S; Ye J; Xi Y; Li J; Liu R; Cai C; Tan Z; Zhang Y; Han Z; Zeng G; Zhong W
Front Immunol; 2022; 13():1046790. PubMed ID: 36505457
[TBL] [Abstract] [Full Text] [Related]
12. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
[TBL] [Abstract] [Full Text] [Related]
13. Circulating exosomal mRNA signatures for the early diagnosis of clear cell renal cell carcinoma.
He X; Tian F; Guo F; Zhang F; Zhang H; Ji J; Zhao L; He J; Xiao Y; Li L; Wei C; Huang C; Li Y; Zhang F; Yang B; Ye H; Wang F
BMC Med; 2022 Aug; 20(1):270. PubMed ID: 36002886
[TBL] [Abstract] [Full Text] [Related]
14. Development of a setd2-related immune prognostic signature in clear cell renal cell carcinoma.
Wang X; Xia Z; Li Z; Zhang C
Medicine (Baltimore); 2022 Aug; 101(31):e29561. PubMed ID: 35945780
[TBL] [Abstract] [Full Text] [Related]
15. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic prognosis for Renal Clear Cell Carcinoma.
Wang Q; Tang H; Luo X; Chen J; Zhang X; Li X; Li Y; Chen Y; Xu Y; Han S
Front Immunol; 2022; 13():890150. PubMed ID: 35686121
[TBL] [Abstract] [Full Text] [Related]
16. Integrative Analysis of the Genomic and Immune Microenvironment Characteristics Associated With Clear Cell Renal Cell Carcinoma Progression: Implications for prognosis and Immunotherapy.
Lin E; Zhu P; Ye C; Huang M; Liu X; Tian K; Tang Y; Zeng J; Cheng S; Liu J; Liu Y; Yu Y
Front Immunol; 2022; 13():830220. PubMed ID: 35677048
[TBL] [Abstract] [Full Text] [Related]
17. A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
Liu W; Ren D; Xiong W; Jin X; Zhu L
J Exp Clin Cancer Res; 2022 Jan; 41(1):38. PubMed ID: 35081978
[TBL] [Abstract] [Full Text] [Related]
18. Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients.
Jiang W; Zeng H; Liu Z; Jin K; Hu B; Chang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
Urol Oncol; 2022 Apr; 40(4):166.e15-166.e25. PubMed ID: 34998671
[TBL] [Abstract] [Full Text] [Related]
19. Risk prediction for metastasis of clear cell renal cell carcinoma using digital multiplex ligation-dependent probe amplification.
Yoshikawa Y; Yamada Y; Emi M; Atanesyan L; Smout J; de Groot K; Savola S; Nakanishi-Shinkai Y; Kanematsu A; Nojima M; Ohmuraya M; Hashimoto-Tamaoki T; Yamamoto S
Cancer Sci; 2022 Jan; 113(1):297-307. PubMed ID: 34687579
[TBL] [Abstract] [Full Text] [Related]
20. The Identification of Zinc-Finger Protein 433 as a Possible Prognostic Biomarker for Clear-Cell Renal Cell Carcinoma.
Heyliger SO; Soliman KFA; Saulsbury MD; Reams RR
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439859
[TBL] [Abstract] [Full Text] [Related]
[Next]